Response to raltegravir-based salvage therapy in HIV-infected patients with hepatitis C virus or hepatitis B virus coinfection

Journal of Antimicrobial Chemotherapy

Volumn 68, Issue 1, 2013, Pages 193-199

  Weimer, Liliana Elena ^a   Fragola, Vincenzo ^a   Floridia, Marco ^a   Guaraldi, Giovanni ^b   Ladisa, Nicoletta ^c   Francisci, Daniela ^d   Bellagamba, Rita ^e   Degli Antoni, Anna ^f   Parruti, Giustino ^g   Giacometti, Andrea ^h   Manconi, Paolo Emilio ⁱ   Vivarelli, Angela ^j   D'Ettorre, Gabriella ^k   Mura, Maria Stella ^l   Cicalini, Stefania ^e   Preziosi, Roberta ^m   Sighinolfi, Laura ⁿ   Verucchi, Gabriella ^o   Libertone, Raffaella ^e   Tavio, Marcello ^p   Sarmati, Loredana ^q   Bucciardini, Raffaella ^a   Angarano, G ^c   Volpe, A ^c   Vullo, V ^k   Ceccarelli, G ^k   Andreoni, M ^q   Delle Rose, D ^q   Tozzi, V ^e   Narciso, P ^e   Petrosillo, N ^e   Pucillo, V ^e   Tommasi, C ^e   Segala, D ⁿ   Armignacco, O ^m   Ferrari, C ^f   Cavalli, A ^f   Sozio, F ^g   Cosentino, L ^g   Ortu, F ⁱ   Viale, P ^o   Tedeschi, S ^o   Manfredi, R ^o   Mannazzu, M ^l   Cattari, G ^l   Del Gobbo, R ^p   Mataloni Paggi, A ^p   Cirioni, O ^h   Marchionni, E ^h   Silvestri, C ^h   Brescini, L ^h   Sebastianelli, S ^h   Baldelli, F ^d   Mercuri, A ^d   Bastianelli, S ^d   Nardini, G ^b   Massella, M ^a   Baroncelli, S ^a   Galluzzo, C M ^a   Pirillo, M F ^a   Mancini, M G ^a   Amici, R ^a   Cara, A ^a   Bona, R ^a   Leone, P ^a   Filati, P ^a   Franco, M ^a   Donnini, S ^a   more..

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^c UNIVERSITY OF BARI   (Italy)

^d UNIVERSITY OF PERUGIA   (Italy)

^e NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^f UNIVERSITY HOSPITAL OF PARMA   (Italy)

^g SPIRITO SANTO HOSPITAL   (Italy)

^h UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

ⁱ UNIVERSITY OF CAGLIARI   (Italy)

^j PISTOIA HOSPITAL   (Italy)

^k SAPIENZA UNIVERSITY OF ROME   (Italy)

^l UNIVERSITY OF SASSARI   (Italy)

^m BELCOLLE HOSPITAL   (Italy)

ⁿ S ANNA HOSPITAL   (Italy)

^o UNIVERSITY OF BOLOGNA   (Italy)

^p OSPEDALI RIUNITI   (Italy)

^q UNIVERSITY OF ROME TOR VERGATA   (Italy)

more..

Author keywords

Antiretroviral therapy; CD4 response; Darunavir; Etravirine; HBV; HCV; HIV resistance; HIV 1; Integrase inhibitors; Liver disease; Maraviroc; Viral hepatitis; Viral load

Indexed keywords

AMINOTRANSFERASE; DARUNAVIR; ETRAVIRINE; MARAVIROC; RALTEGRAVIR; VIRUS RNA;

ADULT; AGED; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; DISEASE DURATION; FEMALE; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; SALVAGE THERAPY; TREATMENT RESPONSE; VIRAL CLEARANCE;

ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; COINFECTION; FEMALE; FOLLOW-UP STUDIES; HEPACIVIRUS; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; SALVAGE THERAPY; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84871242042     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dks341     Document Type: Article

References (14)

1. Rockstroh JK, Mocroft A, Soriano V et al. Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. J Infect Dis 2005; 192: 992-1002.
2. Yacisin K, Maida I, Ríos MJ et al. Hepatitis C virus coinfection does not affect CD4 restoration in HIV-infected patients after initiation of antiretroviral therapy. AIDS Res Hum Retroviruses 2008; 24: 935-40.
3. Fuping G, Wei L, Yang H et al. Impact of hepatitis C virus coinfection on HAART in HIV-infected individuals: multicentric observation cohort. J Acquir Immune Defic Syndr 2010; 54: 137-42.
4. Carmo RA, Guimarães MD, Moura AS et al. The influence of HCV coinfection on clinical, immunological and virological responses to HAART in HIV-patients. Braz J Infect Dis 2008; 12: 173-9.
5. Weis N, Lindhardt BO, Kronborg G et al. Impact of hepatitis C virus coinfection on response to highly active antiretroviral therapy and outcome in HIV-infected individuals: a nationwide cohort study. Clin Infect Dis 2006; 42: 1481-7.
6. D'Arminio Monforte A, Cozzi-Lepri A, Castagna A et al. Risk of developing specific AIDS-defining illnesses in patients coinfected with HIV and hepatitis C virus with or without liver cirrhosis. Clin Infect Dis 2009; 49: 612-22.
7. Vispo E, Mena A, Maida I et al. Hepatic safety profile of raltegravir in HIV-infected patients with chronic hepatitis C. J Antimicrob Chemother 2010; 65: 543-7.
8. Macías J, Neukam K, Portilla J et al. Liver tolerance of raltegravircontaining antiretroviral therapy in HIV-infected patients with chronic hepatitis C. J Antimicrob Chemother 2011; 66: 1346-50.
9. Rockstroh J, Teppler H, Zhao J et al. Safety and efficacy of raltegravir in patients with HIV-1 and hepatitis B and/or C virus coinfection. HIV Med 2012; 13: 127-31.
10. AIDS Clinical Trials Group. Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events. http://www.hptn.org/web%20documents/hptn046/ssp/appendices/appendixe-toxicitytables_daids_ae_gradingtable_finaldec2004.pdf (27 August 2012, date last accessed).
11. Pineda JA, Santos J, Rivero A et al. Liver toxicity of antiretroviral combinations including atazanavir/ritonavir in patients co-infected with HIV and hepatitis viruses: impact of pre-existing liver fibrosis. J Antimicrob Chemother 2008; 61: 925-32.
12. Data Collection on Adverse Events of Anti-HIV drugs (D:A:D) Study Group. Smith CJ, Sabin CA, Lundgren JD et al. Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D Study. AIDS 2010; 24: 1537-48.
13. Hoffmann CJ, Seaberg EC, Young S et al. Hepatitis B and longterm HIV outcomes in coinfected HAART recipients. AIDS 2009; 23: 1881-9.
14. Lucas S. Causes of death in the HAART era. Curr Opin Infect Dis 2012; 25: 36-41.